|Application:||Gene expression microarray analysis|
|Number of samples:||4|
|Release date:||Jul 1 2015|
|Last update date:||Oct 7 2016|
|Diseases:||Bone Marrow Diseases, Leukemia, Plasma Cell, Multiple Myeloma, Neoplasms, Second Primary|
|Dataset link||Assessment of MEK-ERK pathway targeting by BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias [U266 human myeloma cell line]|
To further elucidate the transcriptional programs modulated by BRAF activation in MM, we used the PLX4032 drug to inhibit BRAF activity in U266 human myeloma cell line (HMCL), carrying K601N mutation and showing constitutive activation of MEK/ERK signaling. After confirming its ability to suppress MAPK pathway and myeloma cell proliferation in culture in the U266 cell line, we investigated the specific modulation of gene expression induced by the drug. U266 cells were treated with PLX4032 (30 ÂµM) or DMSO for 12 hours and subjected to gene expression profiling (GEP) analysis by using Affymetrix GeneChip Human Gene 1.0ST arrays.